Concepta (#CPT) – launch of DNA testing service, first test swab kit sees it onto the COVID bandwagon

Concepta acquisition, this is the start of a new broom: Buy as shares will hit 2.5p soon

We shareholders in Concepta (CPT) have suffered long enough but it appears that the new management team led by Penny McCormick is now doing all the right things.

Concepta – ‘confident in opportunity and expertise’?...

Concepta (CPT) has announced results for the first half of 2020, including emphasising “corporate reorganisation and cost reductions to allow funds to be redeployed into commercial efforts” and “new product development focus now on superior App Dx opportunity and wider testing suite”...

Concepta – commercial & costs update, a risk/reward buy?...

Concepta (CPT) has updated on its “commercial activities and successful cost reduction programme, which has allowed additional funds to be channelled into focused commercialisation efforts”...

Concepta - a questioning shareholder questions

I am told great things will happen at Concepta (CPT) soon. But I have been told that by previous managers and they never did. So I hold on to my shares. But I have niggling concerns as does a fellow long suffering shareholder Tony Prynne who has penned the note below flagging up matters the company should address. Tony writes:

Concepta – “Commercial update”, positive steps...

A “Commercial update” from “personalised healthcare company and developer of myLotus®, the UK's most accurate home-use fertility tracking and pregnancy self-testing system”, Concepta* (CPT) including “following the board changes announced in October and November last year, the company has made substantial improvements to its operational structure to best position the business to ensure the commercial success of myLotus”...

Concepta (#CPT) – updates on wider commercial roll-out plans

Concepta – another agreement to increase potential...

Concepta (CPT) has announced “an exclusive global licence agreement with Abingdon Health Limited for the use of its App Dx IP for human pregnancy and fertility”...

Concepta – manufacturing outsourcing further cost saving and to focus on product commercialisation...

We’ve previously noted the new management team at Concepta (CPT) taking cost actions – and now a “Manufacturing outsourcing agreements for myLotus®” announcement…

Concepta (#CPT) – asset sales agreement for “approximately £0.3m” to move to outsourced manufacturing strategy

Concepta – discounted fundraising… baverage down now a STRONG BUY

Concepta (CPT) has announced that it has conditionally, including on shareholders approval, raised a gross £1.9 million (with FIML, a company owned by a trust whose beneficiaries are the dependants of Tom Winnifrith, taking part) to “provide us with a solid platform from which to drive the commercial success of our flagship self-test fertility test myLotus ®”, with CEO Penny McCormick emphasising “I remain confident that we have a business with substantial upside opportunity and these funds will allow us to deliver upon its potential”…

Concepta (#CPT) – conditionally raised £1.9m, including new equity at 0.8p & £0.101m of convertible loan notes

Concepta – “now in a position to deliver upon its potential”?

Concepta (CPT) has updated emphasising “following the appointment of Penny McCormick as Chief Executive Officer and Maddy Kennedy as Chief Financial Officer in the final quarter of last year, the company has made substantial progress to establish an effective operational structure to ensure the commercial success of myLotus®, and to advance new product opportunities”. What is this progress then?...

Concepta Management change - Buy

It has been a bad tip so far but management chance at Concepta (CPT) marks a turning point.  First Matthew Walls, the CEO is going. Now we have the appointments of Penelope ("Penny") McCormick as Chief Executive and Lyn Rees as a Non-Executive Director”. It is emphasised;

Concepta (#CPT) – announces appointments of Penelope (‘Penny’) McCormick as Chief Executive & Lyn Rees as a non-executive

Concepta (#CPT) – Matthew Walls “step down”, company “in the final stages of appointing a highly experienced Chief Executive and additional Non-Executive”

Concepta – financial results need improvement, fertility clinic collaborations to help

Concepta (CPT) has announced results for the first half of 2019 and a “first myLotus® UK Fertility Clinic collaboration”…

Concepta (#CPT) – new CFO appointment as Barbara Spurrier leaves “to spend more time on her other business interests”

Concepta Results – truly dire but that is the rear view mirror: STRONG BUY

Concepta (CPT) has announced its calendar 2018 results which are truly ghastly. But that is all rear view mirror stuff and so at 3.7p the shares are, we suggest, a gamble but a BUY.

As expected piss poor numbers from Concepta (#CPT), but confident on outlook